The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Identification of a novel breast cancer molecular subgroup associated with a deficiency in DNA-damage response.
J. M. Mulligan
Employment or Leadership Position - Almac Diagnostics
L. A. Hill
Employment or Leadership Position - Almac Diagnostics (U)
S. Deharo
Employment or Leadership Position - Almac Diagnostics
F. A. McDyer
Employment or Leadership Position - Almac Diagnostics (U)
T. S. Davison
Employment or Leadership Position - Almac Diagnostics (U)
M. Bylesjo
Employment or Leadership Position - Almac Diagnostics
N. M. Lindor
No relevant relationships to disclose
L. Galligan
Employment or Leadership Position - Almac Diagnostics
T. Delaney
Employment or Leadership Position - Almac Diagnostics
I. A. Halfpenny
Employment or Leadership Position - Almac Diagnostics
V. Farztdinov
Employment or Leadership Position - Almac Diagnostics
N. Goffard
Employment or Leadership Position - Almac Diagnostics
V. Proutski
Employment or Leadership Position - Almac Diagnostics
K. E. Keating
Employment or Leadership Position - Almac Diagnostics
P. B. Mullan
Consultant or Advisory Role - Almac Diagnostics
J. E. Quinn
Research Funding - Almac Diagnostics
P. G. Johnston
Consultant or Advisory Role - Almac Diagnostics
F. J. Couch
No relevant relationships to disclose
D. P. Harkin
Employment or Leadership Position - Almac Diagnostics
R. D. Kennedy
Employment or Leadership Position - Almac Diagnostics